Please try another search
For the three months ended 31 March 2022, Peptron Inc revenues increased from W809.6M to W2.78B. Net loss decreased 61% to W2.03B. Revenues reflect Biotechnology segment increase from W405.8M to W2.45B, foreign segment increase from W2M to W1.98B, South Korea (Country) segment increase of less than 1% to W807.9M. Lower net loss reflects Biotechnology segment loss decrease of 60% to W2.15B.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 477.27 | 799.67 | 683.47 | 695.35 |
Gross Profit | 27.11 | 355.21 | 203.02 | 217.73 |
Operating Income | -4037.81 | -3058.84 | -4172.88 | -4490.92 |
Net Income | -4030.65 | -3261.83 | -4140.3 | -4508.11 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 49909.46 | 52495.98 | 54854.72 | 59076.38 |
Total Liabilities | 17813.09 | 16368.96 | 15280.59 | 15051.73 |
Total Equity | 32096.37 | 36127.01 | 39574.13 | 44024.65 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -2902.61 | -1359.85 | -3189.13 | -3392.14 |
Cash From Investing Activities | 419.1 | -1073.8 | 3829.29 | 5043.06 |
Cash From Financing Activities | -18.54 | -6.34 | -471.29 | -350.8 |
Net Change in Cash | -2489.19 | -2523.46 | 206.64 | 1304.16 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review